{"nctId":"NCT00794157","briefTitle":"Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","startDateStruct":{"date":"2008-11"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"count":347,"armGroups":[{"label":"Indacaterol 150 µg","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol 150 μg capsules"]},{"label":"Indacaterol 300 µg","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol 300 μg capsules"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo capsules"]}],"interventions":[{"name":"Indacaterol 150 μg capsules","otherNames":[]},{"name":"Indacaterol 300 μg capsules","otherNames":[]},{"name":"Placebo capsules","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of moderate-to-severe chronic obstructive pulmonary disease (COPD), as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines and:\n\n  1. Smoking history of at least 20 pack-years.\n  2. Post-bronchodilator forced expiratory volume in 1 second (FEV1) \\< 80% and ≥ 30% of the predicted normal value.\n  3. Post-bronchodilator FEV1/FVC (forced vital capacity) \\< 70%.\n\nExclusion Criteria:\n\n* Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to screening or during the 14 day run-in period prior to randomization.\n* Patients requiring long-term oxygen therapy (\\> 15 hours a day) for chronic hypoxemia.\n* Patients who have had a respiratory tract infection within 6 weeks prior to screening.\n* Patients with concomitant pulmonary disease.\n* Patients with a history of asthma.\n* Patients with diabetes Type I or uncontrolled diabetes Type II.\n* Any patient with lung cancer or a history of lung cancer.\n* Any patient with active cancer or a history of cancer with less than 5 years disease-free survival time.\n* Patients with a history of long QT syndrome or whose QTc interval (Bazett's) measured at screening or randomization is prolonged.\n* Patients who have been vaccinated with live attenuated vaccines within 30 days prior to screening or during the run-in period.\n* Patients unable to successfully use a dry powder inhaler device or perform spirometry measurements.\n\nOther protocol-defined inclusion/exclusion criteria applied to the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of Treatment (Week 12 + 1 Day, Day 85)","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at the end of treatment. The analysis included baseline FEV1, FEV1 pre-dose and 30 minutes post-dose of salbutamol during screening, and FEV1 pre-dose and 60 minutes post-dose of ipratropium during screening as covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.34","spread":"0.024"},{"groupId":"OG001","value":"1.37","spread":"0.023"},{"groupId":"OG002","value":"1.17","spread":"0.025"}]}]}]},{"type":"SECONDARY","title":"Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 2","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at Week 2. The analysis included baseline FEV1, FEV1 pre-dose and 30 minutes post-dose of salbutamol during screening, and FEV1 pre-dose and 60 minutes post-dose of ipratropium during screening as covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.33","spread":"0.023"},{"groupId":"OG001","value":"1.34","spread":"0.023"},{"groupId":"OG002","value":"1.17","spread":"0.024"}]}]}]},{"type":"SECONDARY","title":"Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 4","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at Week 4. The analysis included baseline FEV1, FEV1 pre-dose and 30 minutes post-dose of salbutamol during screening, and FEV1 pre-dose and 60 minutes post-dose of ipratropium during screening as covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.32","spread":"0.024"},{"groupId":"OG001","value":"1.33","spread":"0.022"},{"groupId":"OG002","value":"1.18","spread":"0.024"}]}]}]},{"type":"SECONDARY","title":"Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 8","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at Week 8. The analysis included baseline FEV1, FEV1 pre-dose and 30 minutes post-dose of salbutamol during screening, and FEV1 pre-dose and 60 minutes post-dose of ipratropium during screening as covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.30","spread":"0.029"},{"groupId":"OG001","value":"1.32","spread":"0.027"},{"groupId":"OG002","value":"1.14","spread":"0.030"}]}]}]},{"type":"SECONDARY","title":"Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 (Day 84)","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 50 and 15 minutes pre-dose at the end of treatment. The analysis included baseline FEV1, FEV1 pre-dose and 30 minutes post-dose of salbutamol during screening, and FEV1 pre-dose and 60 minutes post-dose of ipratropium during screening as covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.34","spread":"0.032"},{"groupId":"OG001","value":"1.34","spread":"0.030"},{"groupId":"OG002","value":"1.13","spread":"0.031"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":114},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis","Cough"]}}}